Angiotensinergic stimulation of vascular endothelium in mice causes hypotension, bradycardia, and attenuated angiotensin response.
It is not clear whether endothelial cell (EC) activation by the hormone angiotensin II (Ang II) modulates contraction of vascular smooth muscle cells (VSMCs) in the vasculature and whether impairment of this regulation in vivo contributes to hypertension. Delineation of the actions of Ang II through the type 1 receptor (AT1R) on ECs in the blood vessels has been a challenging problem because of the predominance of the AT1R functions in VSMCs that lie underneath the endothelium. We have obviated this limitation by generating transgenic (TG) mice engineered to target expression of the constitutively active N111G mutant AT1R only in ECs. In these TG mice, the enhanced angiotensinergic signal in ECs without infusion of Ang II resulted in hypotension and bradycardia. The pressor response to acute infusion of Ang II was significantly reduced. Increased expression of endothelial nitric oxide synthase and production of hypotensive mediators, nitric oxide and cyclic guanosine monophosphate, cause these phenotypes. Hypotension and bradycardia observed in the TG mice could be rescued by treatment with an AT1R-selective antagonist. Our results imply that the Ang II action by means of EC-AT1R is antagonistic to vasoconstriction in general, and it may moderate the magnitude of functional response to Ang II in VSMCs. This control mechanism in vivo most likely is a determinant of altered hemodynamic regulation involved in endothelial dysfunction in hypertensive cardiovascular disease.
Ramchandran
Ramaswamy
R
Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
Takezako
Takanobu
T
Saad
Yasser
Y
Stull
Linda
L
Fink
Bruno
B
Yamada
Hirotsugu
H
Dikalov
Sergey
S
Harrison
David G
DG
Moravec
Christine
C
Karnik
Sadashiva S
SS
D000809:Angiotensins / Q000378:metabolism*; D000818:Animals; D001794:Blood Pressure; D001919:Bradycardia / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000378:metabolism*; D015870:Gene Expression; D007022:Hypotension / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology; D051379:Mice; D008822:Mice, Transgenic; D009569:Nitric Oxide / Q000097:blood; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism; D010641:Phenotype; D044140:Receptor, Angiotensin, Type 1 / Q000235:genetics / Q000378:metabolism; D042810:Receptor, TIE-1 / Q000235:genetics / Q000378:metabolism
D000809:Angiotensins; D044140:Receptor, Angiotensin, Type 1; D009569:Nitric Oxide; D052250:Nitric Oxide Synthase Type III; D042810:Receptor, TIE-1